Clinical Observation of Chemotherapy Combined with Bevacizumab in the Treatment of Colorectal Cancer Liver Metastases
10.6039/j.issn.1001-0408.2015.35.34
- VernacularTitle:化疗联合贝伐珠单抗治疗结直肠癌肝转移的临床观察
- Author:
Ning MA
;
Chaojie WANG
;
Yun ZHOU
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Colorectal cancer;
Combined chemotherapy;
Liver metastasis
- From:
China Pharmacy
2015;26(35):4995-4997
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe therapeutic efficacy and liver toxicity of chemotherapy combined with bevacizumab in the treatment of colorectal cancer liver metastases (CLMs). METHODS:126 CLMs patients were selected and randomly divided into chemotherapy group(54 cases)and combination group(72 cases). Chemotherapy group received FOLFOXIRI regimen:irinotecan 165 mg/m2+oxaliplatin 85 mg/m2+calcium folinate 200 mg/m2+fluorouracil 2 g. Combination group was additionally given bevaci-zumab 5 mg/kg one day before chemotherapy on the basis of FOLFOXIRI regimen. A treatment course of 2 groups lasted for 2 weeks,and both received 12 courses of treatment. The pathological response,survival rate and toxic reactions caused by chemother-apy were compared between 2 groups. RESULTS:Pathological complete response proportion,tumor remission rating(TRG),the proportion of patients with tumor necrosis rate ≥50% in combination group were significantly higher than chemotherapy group, with statistical significance (P<0.01). The proportion of TRG4-5,TRG 1-3 progression-free survival in combination group were significantly higher than chemotherapy group,with statistical significance (P<0.05). The incidence of liver parenchymal necrosis in combination group was significantlg higher than chemotherapy group,there was statistical significance (P>0.05). CONCLU-SIONS:Chemotherapy combined with bevacizumab can improve pathological response and the incidence of CLMs necrosis and doesn't increase liver toxicity.
